The product will be marketed under store brand labels and is comparable to McNeil Consumer Healthcare’s children’s Zyrtec Oral Solution, 1mg/mL, indicated for indoor and outdoor allergy and hives relief. The company expects to begin shipping the product immediately.
Joseph Papa, Perrigo’s chairman and CEO, said: “This approval reflects our strategy to be first to market with the important products that make quality healthcare more affordable for our customers.”